Trials / Unknown
UnknownNCT06222125
A Study of HB0025 Injection in Patients With Advanced Renal Cancer
A Phase II, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of HB0025 in Patients With Advanced Renal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Huabo Biopharm Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
It is a phase II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0025 in patients with advanced clear cell renal cell carcinoma (ccRCC).
Detailed description
The phase II study will enroll subjects with advanced clear cell renal cell carcinoma (ccRCC) who have progressing tumor after standard therapy and have no better treatment option.This study will set up 2 dose groups.HB0025 injection is administered once every 2 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HB0025 | HB0025 IV every 2 weeks (q2w) |
Timeline
- Start date
- 2023-01-30
- Primary completion
- 2025-01-30
- Completion
- 2025-12-30
- First posted
- 2024-01-24
- Last updated
- 2024-01-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06222125. Inclusion in this directory is not an endorsement.